Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[The economic evaluation of prostatic hyperthermia]

Y Merliere1, C Viens-Bitker, J Houee

  • 1Département du Contrôle de Gestion, Direction des Finances de l'Assistance Publique-Hôpitaux de Paris AP-HP.

Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|August 1, 1994
PubMed
Summary

This study found that hyperthermia treatment costs for Benign Prostatic Hyperplasia (BPH) vary significantly by equipment. Drug treatments are more cost-effective for BPH management compared to hyperthermia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Is transition from pure laparoscopic to robotic-assisted radical prostatectomy associated with increase of surgical procedures for urinary incontinence and erectile dysfunction?]

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2018
Same author

Live surgery: highly educational or harmful?

World journal of urology·2017
Same author

[Not Available].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2015
Same author

[Not Available].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2015
Same author

[Oncological outcome of radical cystectomy for BCG failure compared to primary invasive disease].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2013
Same author

The use of mannitol in partial and live donor nephrectomy: an international survey.

World journal of urology·2012

Area of Science:

  • Health Economics
  • Urology
  • Medical Technology Assessment

Background:

  • Benign Prostatic Hyperplasia (BPH) is a common condition in aging men.
  • Hyperthermia is an alternative treatment modality for BPH.
  • Assessing the cost-effectiveness of different BPH treatments is crucial for healthcare resource allocation.

Purpose of the Study:

  • To evaluate the hospital costs associated with treating Benign Prostatic Hyperplasia (BPH) using hyperthermia.
  • To compare the cost-effectiveness of hyperthermia versus traditional drug treatments for BPH.

Main Methods:

  • A randomized clinical trial comparing hyperthermia to sham treatment was conducted.
  • Hospital costs were analyzed, including staff salaries, supplies, overhead, and capital expenses.

Related Experiment Videos

  • Cost data was collected and analyzed by the Committee for Evaluation and Diffusion of Innovative Technologies (CEDIT).

    • Main Results:

    • The cost per hyperthermia session ranged from FF 1200 to FF 5300.
    • The total cost per hyperthermia treatment varied from FF 2500 to FF 9700, depending on the equipment utilized.
    • Annual drug treatment costs for BPH were estimated between FF 2600 and FF 2900.

    Conclusions:

    • Significant cost variations exist for hyperthermia BPH treatment based on equipment.
    • Clinical evidence did not support superior efficacy for more expensive hyperthermia devices.
    • Pharmacological treatments appear to be a more cost-effective option for managing BPH compared to hyperthermia.